TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample. Read More...

TruSight Tumor 170 Kit, For Use with NextSeq (24 Samples)


TruSight Tumor 170 Kit (24 Samples)


TruSight Tumor 170 Kit, For Use with NextSeq plus Watson for Genomics


TruSight Tumor 170 Kit plus Watson for Genomics


Product Highlights

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

  • Comprehensive Coverage of Cancer-Related Variants
    Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
  • Accurate Results from Low-Quality Samples1
    Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.

Frequently Purchased Together



仪器 推荐的样本数 读长
NextSeq 550 System 每次运行的样本(高通量):16(8个DNA样本和8个RNA样本),10(DNA样本),16(RNA样本) 2 × 101 bp (最大推荐值)
HiSeq 2500 System 每次运行的样本(快速运行):12(6个DNA样本和6个RNA样本),6(DNA样本),12(RNA样本) 2 × 101 bp (最大推荐值)


TruSight Tumor 170 TruSight Tumor 15 TruSight Oncology 500
变异种类 基因融合, 插入缺失, 单核苷酸多态性(SNP), 结构变异, 拷贝数变异(CNV), 体细胞变异 体细胞变异, 插入缺失 插入缺失, 体细胞变异, 单核苷酸多态性(SNP), 基因融合
技术 测序 测序 测序
方法 靶向RNA测序 , 靶向DNA测序 扩增子测序 , 靶向DNA测序 靶向RNA测序 , 靶向DNA测序 , 免疫测序
物种类别 人类 人类 人类
特殊的样本类型 低起始量样本, FFPE组织 FFPE组织 FFPE组织
癌症类型 实体瘤 实体瘤 泛癌
系统兼容性 NextSeq 550 , NextSeq 500 , HiSeq 2500 MiniSeq , 研究模式下的MiSeqDx , MiSeq , MiSeq NextSeq 500 , NextSeq 550

Method-Specific Workflow Example


Case Studies

Scientific Posters

AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden

Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.

Learn More

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More

Related Products

TruSight Oncology 500


TruSight RNA Pan-Cancer

Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.

TruSight RNA Fusion Panel

Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.

  1. Beta study. Data on file. March 2017.